Glycopeptide-resistant Enterococcus faecium infections in paediatric liver transplant recipients: safety and clinical efficacy of quinupristin/dalfopristin

A Verma; A Dhawan; J Philpott-Howard; M Rela; N Heaton; G Mieli-Vergani; J Wade

doi:10.1093/jac/47.1.105

Glycopeptide-resistant Enterococcus faecium infections in paediatric liver transplant recipients: safety and clinical efficacy of quinupristin/dalfopristin

A Verma, A Dhawan, J Philpott-Howard, M Rela, N Heaton, G Mieli-Vergani, J Wade

Infectious Diseases

Research output: Contribution to journal › Article › peer-review

25 Citations (Scopus)

Abstract

We describe our experience of quinupristin/dalfopristin for glycopeptide-resistant Enterococcus faecium (GREF) infections in 19 paediatric liver transplant recipients. The median patient age was 2 years and all were receiving immunosuppressive regimens. Quinupristin/dalfopristin was well tolerated and complete resolution of infection was seen in 74% of patients. Side-effects included reversible elevation of serum alkaline phosphatase, skin rash, itching, diarrhoea and vomiting, but therapy was not withdrawn from any patient. Quinupristin/dalfopristin appears safe and efficacious in critically ill immunocompromised children with renal or hepatic Impairment.

Original language	English
Pages (from-to)	105 - 108
Number of pages	4
Journal	Journal of Antimicrobial Chemotherapy
Volume	47
Issue number	1
DOIs	https://doi.org/10.1093/jac/47.1.105
Publication status	Published - 2001

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/jac/47.1.105

Cite this

@article{06be206b2e174364a04a914bc0eccf84,

title = "Glycopeptide-resistant Enterococcus faecium infections in paediatric liver transplant recipients: safety and clinical efficacy of quinupristin/dalfopristin",

abstract = "We describe our experience of quinupristin/dalfopristin for glycopeptide-resistant Enterococcus faecium (GREF) infections in 19 paediatric liver transplant recipients. The median patient age was 2 years and all were receiving immunosuppressive regimens. Quinupristin/dalfopristin was well tolerated and complete resolution of infection was seen in 74% of patients. Side-effects included reversible elevation of serum alkaline phosphatase, skin rash, itching, diarrhoea and vomiting, but therapy was not withdrawn from any patient. Quinupristin/dalfopristin appears safe and efficacious in critically ill immunocompromised children with renal or hepatic Impairment.",

author = "A Verma and A Dhawan and J Philpott-Howard and M Rela and N Heaton and G Mieli-Vergani and J Wade",

year = "2001",

doi = "10.1093/jac/47.1.105",

language = "English",

volume = "47",

pages = "105 -- 108",

journal = "Journal of Antimicrobial Chemotherapy",

publisher = "Oxford University Press (OUP)",

number = "1",

}

TY - JOUR

T1 - Glycopeptide-resistant Enterococcus faecium infections in paediatric liver transplant recipients: safety and clinical efficacy of quinupristin/dalfopristin

AU - Verma, A

AU - Dhawan, A

AU - Philpott-Howard, J

AU - Rela, M

AU - Heaton, N

AU - Mieli-Vergani, G

AU - Wade, J

PY - 2001

Y1 - 2001

N2 - We describe our experience of quinupristin/dalfopristin for glycopeptide-resistant Enterococcus faecium (GREF) infections in 19 paediatric liver transplant recipients. The median patient age was 2 years and all were receiving immunosuppressive regimens. Quinupristin/dalfopristin was well tolerated and complete resolution of infection was seen in 74% of patients. Side-effects included reversible elevation of serum alkaline phosphatase, skin rash, itching, diarrhoea and vomiting, but therapy was not withdrawn from any patient. Quinupristin/dalfopristin appears safe and efficacious in critically ill immunocompromised children with renal or hepatic Impairment.

AB - We describe our experience of quinupristin/dalfopristin for glycopeptide-resistant Enterococcus faecium (GREF) infections in 19 paediatric liver transplant recipients. The median patient age was 2 years and all were receiving immunosuppressive regimens. Quinupristin/dalfopristin was well tolerated and complete resolution of infection was seen in 74% of patients. Side-effects included reversible elevation of serum alkaline phosphatase, skin rash, itching, diarrhoea and vomiting, but therapy was not withdrawn from any patient. Quinupristin/dalfopristin appears safe and efficacious in critically ill immunocompromised children with renal or hepatic Impairment.

U2 - 10.1093/jac/47.1.105

DO - 10.1093/jac/47.1.105

M3 - Article

VL - 47

SP - 105

EP - 108

JO - Journal of Antimicrobial Chemotherapy

JF - Journal of Antimicrobial Chemotherapy

IS - 1

ER -

Glycopeptide-resistant Enterococcus faecium infections in paediatric liver transplant recipients: safety and clinical efficacy of quinupristin/dalfopristin

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this